212 related articles for article (PubMed ID: 32770099)
41. ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances.
Camacho E; Hernández L; Hernández S; Tort F; Bellosillo B; Beà S; Bosch F; Montserrat E; Cardesa A; Fernández PL; Campo E
Blood; 2002 Jan; 99(1):238-44. PubMed ID: 11756177
[TBL] [Abstract][Full Text] [Related]
42. Characterization of genetic changes in MCL by interphase FISH on tissue sections.
Sander B; Wallblom A; Ekroth A; Porwit A; Kimby E
Leuk Lymphoma; 2007 Jul; 48(7):1344-52. PubMed ID: 17613764
[TBL] [Abstract][Full Text] [Related]
43. Familial lymphoid neoplasms in patients with mantle cell lymphoma.
Tort F; Camacho E; Bosch F; Harris NL; Montserrat E; Campo E
Haematologica; 2004 Mar; 89(3):314-9. PubMed ID: 15020270
[TBL] [Abstract][Full Text] [Related]
44. NOTCH Signaling in Mantle Cell Lymphoma: Biological and Clinical Implications.
Deshotels L; Safa FM; Saba NS
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373427
[TBL] [Abstract][Full Text] [Related]
45. Subclonal evolution of a classical Hodgkin lymphoma from a germinal center B-cell-derived mantle cell lymphoma.
Schneider S; Crescenzi B; Schneider M; Ascani S; Hartmann S; Hansmann ML; Falini B; Mecucci C; Tiacci E; Küppers R
Int J Cancer; 2014 Feb; 134(4):832-43. PubMed ID: 23929122
[TBL] [Abstract][Full Text] [Related]
46. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma.
Chiarle R; Budel LM; Skolnik J; Frizzera G; Chilosi M; Corato A; Pizzolo G; Magidson J; Montagnoli A; Pagano M; Maes B; De Wolf-Peeters C; Inghirami G
Blood; 2000 Jan; 95(2):619-26. PubMed ID: 10627471
[TBL] [Abstract][Full Text] [Related]
47. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
Oncotarget; 2017 Apr; 8(17):27997-28007. PubMed ID: 28427202
[TBL] [Abstract][Full Text] [Related]
48. A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial.
Bomben R; Ferrero S; D'Agaro T; Dal Bo M; Re A; Evangelista A; Carella AM; Zamò A; Vitolo U; Omedè P; Rusconi C; Arcaini L; Rigacci L; Luminari S; Piccin A; Liu D; Wiestner A; Gaidano G; Cortelazzo S; Ladetto M; Gattei V
Haematologica; 2018 May; 103(5):849-856. PubMed ID: 29472356
[TBL] [Abstract][Full Text] [Related]
49. Delineation of distinct tumour profiles in mantle cell lymphoma by detailed cytogenetic, interphase genetic and morphological analysis.
Katzenberger T; Kienle D; Stilgenbauer S; Höller S; Schilling C; Mäder U; Puppe B; Petzoldt C; Sander S; Bullinger L; Stöcklein H; Kalla J; Hartmann E; Adam P; Ott MM; Müller-Hermelink HK; Rosenwald A; Ott G
Br J Haematol; 2008 Aug; 142(4):538-50. PubMed ID: 18564361
[TBL] [Abstract][Full Text] [Related]
50. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
[TBL] [Abstract][Full Text] [Related]
51. Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome.
Rubio-Moscardo F; Climent J; Siebert R; Piris MA; Martín-Subero JI; Nieländer I; Garcia-Conde J; Dyer MJ; Terol MJ; Pinkel D; Martinez-Climent JA
Blood; 2005 Jun; 105(11):4445-54. PubMed ID: 15718413
[TBL] [Abstract][Full Text] [Related]
52. Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network.
Hoster E; Rosenwald A; Berger F; Bernd HW; Hartmann S; Loddenkemper C; Barth TF; Brousse N; Pileri S; Rymkiewicz G; Kodet R; Stilgenbauer S; Forstpointner R; Thieblemont C; Hallek M; Coiffier B; Vehling-Kaiser U; Bouabdallah R; Kanz L; Pfreundschuh M; Schmidt C; Ribrag V; Hiddemann W; Unterhalt M; Kluin-Nelemans JC; Hermine O; Dreyling MH; Klapper W
J Clin Oncol; 2016 Apr; 34(12):1386-94. PubMed ID: 26926679
[TBL] [Abstract][Full Text] [Related]
53. TCL1 expression predicts overall survival in patients with mantle cell lymphoma.
Shin SJ; Roh J; Cha HJ; Choi YD; Kim JM; Min SK; Kim JE; Eom DW; Lee H; Kim HJ; Yoon DH; Suh C; Huh J
Eur J Haematol; 2015 Dec; 95(6):583-94. PubMed ID: 25688912
[TBL] [Abstract][Full Text] [Related]
54. Clonal heterogeneity of mantle cell lymphoma revealed by array comparative genomic hybridization.
Liu F; Yoshida N; Suguro M; Kato H; Karube K; Arita K; Yamamoto K; Tsuzuki S; Oshima K; Seto M
Eur J Haematol; 2013 Jan; 90(1):51-8. PubMed ID: 23110670
[TBL] [Abstract][Full Text] [Related]
55. Detection of gene copy number aberrations in mantle cell lymphoma by a single quantitative multiplex PCR assay: clinicopathological relevance and prognosis value.
Jardin F; Picquenot JM; Parmentier F; Ruminy P; Cornic M; Penther D; Bertrand P; Lanic H; Cassuto O; Humbrecht C; Lemasle E; Wautier A; Bastard C; Tilly H
Br J Haematol; 2009 Sep; 146(6):607-18. PubMed ID: 19594747
[TBL] [Abstract][Full Text] [Related]
56. Treatment approaches for patients with TP53-mutated mantle cell lymphoma.
Lew TE; Minson A; Dickinson M; Handunnetti SM; Blombery P; Khot A; Anderson MA; Ritchie D; Tam CS; Seymour JF
Lancet Haematol; 2023 Feb; 10(2):e142-e154. PubMed ID: 36725119
[TBL] [Abstract][Full Text] [Related]
57. Association of red blood cell distribution width and outcomes in patients with mantle cell lymphoma.
Miao Y; Zhou XH; Guo JJ; Sun Q; Shi K; Wu JZ; Zhu HY; Wang L; Fan L; Xu W; Li JY
Cancer Med; 2019 Jun; 8(6):2751-2758. PubMed ID: 30980510
[TBL] [Abstract][Full Text] [Related]
58. Differential PAX5 levels promote malignant B-cell infiltration, progression and drug resistance, and predict a poor prognosis in MCL patients independent of CCND1.
Teo AE; Chen Z; Miranda RN; McDonnell T; Medeiros LJ; McCarty N
Leukemia; 2016 Mar; 30(3):580-93. PubMed ID: 26073757
[TBL] [Abstract][Full Text] [Related]
59. The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial.
Roider T; Wang X; Hüttl K; Müller-Tidow C; Klapper W; Rosenwald A; Stewart JP; de Castro DG; Dreger P; Hermine O; Kluin-Nelemans HC; Grabe N; Dreyling M; Pott C; Ott G; Hoster E; Dietrich S
Int J Cancer; 2021 Jan; 148(1):150-160. PubMed ID: 32638373
[TBL] [Abstract][Full Text] [Related]
60. Prognostic Role of CDKN2A Deletion and p53 Expression and Association With MIPIb in Mantle Cell Lymphoma.
Gaudio F; Dicataldo M; Di Giovanni F; Cazzato G; d'Amati A; Perrone T; Masciopinto P; Laddaga FE; Musto P; Maiorano E; Ingravallo G
Clin Lymphoma Myeloma Leuk; 2023 Aug; 23(8):599-605. PubMed ID: 37147150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
